NCT04435483 is a Phase 1 clinical trial of Acalabrutinib Treatment A in Pharmacokinetics, sponsored by AstraZeneca.

Who is sponsoring NCT04435483?

NCT04435483 is sponsored by AstraZeneca.

What drugs are being tested in NCT04435483?

Interventions in NCT04435483: Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C.

What condition does NCT04435483 study?

NCT04435483 studies Pharmacokinetics, Bioavailability.

Is NCT04435483 still recruiting?

NCT04435483 is currently completed. Last updated 22 July 2020.

Last reviewed 2020-07-22 · How we verify

NCT04435483

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers

Completed Phase 1 Last updated 22 July 2020

What this trial tests

Phase 1 trial testing Acalabrutinib Treatment A in Pharmacokinetics in 39 participants. Completed in 26 June 2020.

Timeline

22 May 2020

Primary endpoint
26 June 2020

26 June 2020

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	39
Start date	22 May 2020
Primary completion	26 June 2020
Estimated completion	26 June 2020
Sites	1 location across United States

Drugs / interventions tested

Acalabrutinib Treatment A — full drug profile →
Acalabrutinib Treatment B — full drug profile →
Acalabrutinib Treatment C — full drug profile →

Conditions studied

Pharmacokinetics — all drugs for Pharmacokinetics →
Bioavailability — all drugs for Bioavailability →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 55, any sex, with Pharmacokinetics or Bioavailability. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being conducted to support the clinical development of acalabrutinib in patients who are unable to swallow capsule and require nasogastric (NG) tube placement.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Acalabrutinib Treatment A

Trials testing the same drug.

NCT04564040 — A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Acti · Phase 1 · completed

Other recruiting trials for Pharmacokinetics

Currently open trials in the same condition.

NCT07583407 — Pharmacokinetics of Kava and Kratom Alone and in Combination · NA · recruiting
NCT07422285 — Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Do · Phase 1 · recruiting
NCT07060209 — Food Effect on PK of DW-1021 (Pelubiprofen 45 mg / Tramadol 45.9 mg) in Healthy Adults · Phase 1 · recruiting
NCT06859723 — High Potency Cannabis: Acute and Protracted Effects · Phase 1 · recruiting
NCT06733675 — Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination · Phase 1 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04435483 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 22 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04435483.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing